Associated Factors With Uremic Pruritus in Chronic Hemodialysis Patients: A Single-Center Observational Study

Muhammad Sohaib Asghar 1, FNU Avinash 2, Manjeet Singh 3, Muhammad Ali Siddiqui 3, Syed Adef Hassan 4, Shahid Iqbal 5, Syeda Ghazala Irshad 6, Mahrulk Zehra 6, Kainat Siddiqui 6, Uzma Rasheed 6

1. Internal Medicine, Dow University Hospital, Karachi, PAK. 2. Medicine and Surgery, Liaquat National Hospital and Medical College, Karachi, PAK. 3. Internal Medicine, Liaquat National Hospital and Medical College, Karachi, PAK. 4. Internal Medicine, University of Louisville, Louisville, USA. 5. Forensic Medicine, Bacha Khan Medical College, Mardan, PAK. 6. Internal Medicine, Dow University of Health Sciences, Dow International Medical College, Karachi, PAK

Corresponding author: Shahid Iqbal, zain696.si@gmail.com

Abstract

Background and objectives

Uremic pruritus is a recurrent and delicate manifestation in patients suffering from end-stage renal disease. It is a consequence of multiple factors, primarily comprising of metabolic factors and complement activation along with interleukins. The objective of our study was to find out the associated factors of uremic pruritus in chronic hemodialysis patients. The secondary aim was to obtain cut-off values of all the markers predicting pruritus.

Materials and methods

A cross-sectional observational study was conducted in the nephrology department of a tertiary care hospital including 135 patients. The current occurrence of pruritus was diagnosed on the basis of a validated and reliable scale of pruritus among chronic kidney disease (CKD) patients in the local language. Multivariable logistic regression and receiver operating characteristic analysis were conducted to decipher the required objectives.

Results

Study participants had a mean age of 56.29 ± 10.51 years with 56.3% males and 43.7% females. Hypertension was frequent comorbidity (75.6%) followed by diabetes (51.9%). Mean body mass index (BMI), duration of CKD diagnosis, and hemodialysis onset were 26.55 ± 5.37 kg/m², 6.58 ± 5.65 years, and 3.32 ± 2.09 years respectively. Pruritus was reported in 37.0% of the study participants. On multivariate logistic regression, presence of skin allergy (aOR: 8.100 [2.926-22.420], p<0.001), phosphate >4.5 mg/dL (aOR: 3.889 [1.118-12.69], p=0.033), female gender (aOR: 3.592 [1.337-9.655], p=0.011), albumin <3.5 g/dL (aOR: 2.987 [1.156-7.716], p=0.024) and potassium >5.1 mEq/L (aOR: 2.934 [1.030-8.355], p=0.044) were found significantly associated with pruritus.

Conclusion

Many factors were linked to pruritus in hemodialysis patients in the current study. The current study also significantly correlated certain factors with pruritus independently.

Introduction

Uremic pruritus, also recognized as chronic kidney disease-associated pruritus (CKD-aP), is a recurrent manifestation in patients suffering from end-stage renal disease [1,2]. In the 1970s, around 85% of sufferers of chronic kidney disease developed CKD-aP [1]. Pruritus encountered by patients of chronic kidney disease (CKD) is a consequence of multiple factors, primarily metabolic i.e., hypercalcemia, hyperphosphatemia, hypermagnesemia, secondary hyperparathyroidism, aggregation of itch-inducing mediators such as substance P (a neuropeptide), histamine, and complement activation along with interleukins [2-4]. The quality of CKD-aP varies from patient to patient, being unremitting, immense, and incurable while in many sufferers it can be momentary or restricted to a particular region of the body [5]. In patients with end-stage renal disease, pruritus develops within six months of undergoing hemodialysis [5]. Along with affecting the quality of life and sleep in patients with CKD, pruritus is also recognized as a marker of poor prognosis in hemodialysis patients [2,4]. About 25% of patients suffering from end-stage renal disease develop pruritus during or after undergoing dialysis [4]. Hyperphosphatemia is an extensive complication of end-stage renal disease, if left uncured, can lead to the development of bone pain, pruritus, and clinically deteriorating...
secondary hyperparathyroidism along with calcification of heart and blood vessels [4,6].

In patients with end-stage renal disease, hyperphosphatemia is a consequence of the underexcretion of phosphorous ions in urine to a level below intestinal absorption [4,5]. Impairment in process of renal phosphate excretion disrupts the control of phosphorous concentration in the body of particularly those patients without residual renal function (RFF) [6]. Dialysis gets rid of one-third concentration of phosphorus while remaining levels are contained by utilization of phosphate binders and dietary restrictions [4,6]. Phosphorus binders inhibit the absorption of phosphorus from the intestines thus regulating the levels of phosphorus in patients with end-stage renal disease [4,6]. Excessive concentration of phosphorus in patients with end-stage renal disease is a marker associated with mortality [6]. Secondary hyperparathyroidism is a prevalent complication endured by patients of end-stage renal disease due to decline in kidney function, abnormality in phosphorus clearance from the body, and inability to bioactivate vitamin D [7]. Cascade of events i.e., increase in extracellular levels of phosphate, declined concentration of ionized calcium in extracellular fluid, significantly decreased calcitriol levels triggers the synthesis of parathyroid hormone (PTH) along with its secretion [6,7]. Extensive secretion of parathyroid hormone leads to hyperplasia of the gland, thus with the advancement of the disease, downregulation of vitamin D receptors (VDR) and calcium-sensing receptors (CaR) occurs resulting in impairment of control of parathyroid cell function in renal disease patients [8]. Disruption in parathyroid hormone levels (PTH) in patients of chronic kidney disease results in multifaceted complications i.e., pruritus, renal osteodystrophy, neuropathy, cardiac disorders, and vascular calcification, rendering it as uremic toxin [7,8]. Interventions, in order to curtail the toxic effects of hyperparathyroidism, comprise of modification by dietary intake of calcium and phosphorus, dialysis, active vitamin D compounds intake along with analogs, phosphate binders, calcimimetics, and bisphosphonates. Parathyroidectomy is opted as a surgical intervention in case of worsening condition or severe secondary hyperparathyroidism [7,8].

The objective of the current study was to find out the associated factors of uremic pruritus in chronic hemodialysis patients. The secondary aim was to obtain cut-off values for all the markers predicting pruritus. There isn’t any data published similar to the present study’s objective of obtaining cut-offs, hence it justifies the importance of this analysis.

**Materials And Methods**

A cross-sectional observational, descriptive study was conducted in the nephrology department of a tertiary care hospital having one of the largest dialysis units in the city. Above 200 patients are enrolled in this dialysis center for regular dialysis. A sample size of 152 was calculated by using a Rao-soft sample size calculator ([RaoSoft Inc., Seattle, WA](http://www.raosoft.com/samplesize.html)), with a population size of 200, a response distribution of 50%, and a confidence interval of 95%. Ethical approval was taken in this study from the institutional review board of Dow University Hospital (IRB/DUH/2021/742/021), and consent to participate has been taken from all the participants.

A proforma was designed having two sections; the first section covered demographic details including name (as optional), age (in years), gender, body mass index (BMI), co-morbidities including hypertension, diabetes, status of hemodialysis, and duration of CKD. While the second section includes the laboratory markers (including serum urea, creatinine, PTH, potassium, albumin, uric acid, and calcium). These laboratory markers were recorded by a retrospective chart review with a maximum limit of one month prior to the recruitment. The study excluded all the patients diagnosed with viral hepatitis, chronic liver disease, alcohol use, or any other liver morbidity (biliary obstructive diseases), persistent use of topical therapies other than steroids or calamine lotion, as shown in Figure 1.
The study participants were included via a non-probability consecutive sampling technique. The criteria for inclusion were baseline estimated glomerular filtration rate (eGFR) below 15 ml/min/1.73m² and been on hemodialysis for at least one year. Patients on peritoneal dialysis were excluded. The current occurrence of pruritus was diagnosed on the basis of a validated and reliable scale of pruritus among CKD patients in the local language (Urdu) \[9\].

After collection, the data was analyzed using SPSS Statistics version 25.0 (IBM Corp., Armonk, NY), and results were obtained. The descriptive figures were presented as mean and standard deviation (SD), categorical data were presented as frequency (percentages). Normality of data was determined by Kolmogorov-Smirnov test. Univariate logistic regression was applied to all the study variables with pruritus as dependent variable and unadjusted crude odds ratio (OR) were obtained, further only significant factors were adjusted for a multivariate regression model to obtain adjusted odds ratio (aOR) along with 95% confidence interval (considered significant if p-value <0.05 [two-tailed]). A receiver operating characteristic (ROC) analysis was performed to obtain cut-off levels of the biomarkers associated with pruritus. Laboratory values were also categorized by 2x2 contingency tables to obtain appropriate sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

**Results**

A total of 135 participants met the inclusion criteria with a mean age of 56.29 ± 10.51 years with 56.3% males and 43.7% females. Hypertension was the most frequent comorbidity (75.6%) followed by diabetes (51.9%). Mean BMI, duration of CKD diagnosis, and hemodialysis onset were 26.55 ± 5.37 kg/m², 6.58 ± 3.65 years, and 3.32 ± 2.09 years respectively. Pruritus was reported in 37.0% of the study participants, among whom suffered on daily basis (25.2%), once weekly (7.4%), and once monthly (4.4%). Study variables included a previous history of skin allergy (30.4%), use of calamine lotion (57.7%), topical steroids (10.4%), erythropoietin (60.0%), connective tissue disorder (3.7%), thrice-weekly dialysis (51.9%) and twice-weekly dialysis frequency (48.1%). The mean levels of various biochemical markers and their deranged frequencies are given in Table 1.
| Variables                                      | Descriptives/Frequency |
|------------------------------------------------|------------------------|
| Mean age (in years)                           | 56.29 ± 10.51          |
| Age>50 years                                   | n=90 (66.7%)           |
| Female gender                                  | n=59 (43.7%)           |
| Diabetes                                       | n=70 (51.9%)           |
| Hypertension                                   | n=102 (75.6%)          |
| Body mass index (kg/m^2)                      | 26.55 ± 5.37           |
| BMI >26.0 kg/m^2                               | n=74 (54.8%)           |
| Duration of CKD diagnosis (in years)           | 6.58 ± 3.65            |
| Duration of hemodialysis onset (in years)      | 3.32 ± 2.09            |
| Mean estimated GFR ml/min/1.73m^2              | 13.76 ± 1.61           |
| Phosphate (mg/dL)                              | 5.56 ± 2.29            |
| Phosphate >4.5 mg/dL                           | n=83 (61.5%)           |
| Parathyroid hormone (pg/mL)                    | 598.17 ± 463.29        |
| Parathyroid hormone >300 pg/mL                 | n=101 (74.8%)          |
| Albumin (g/L)                                  | 3.55 ± 0.50            |
| Albumin <3.5 g/L                               | n=62 (45.9%)           |
| Calcium (mg/dL)                                | 8.22 ± 0.88            |
| Calcium <8.5 mg/dL                             | n=99 (73.3%)           |
| Uric acid (mg/dL)                              | 6.44 ± 1.09            |
| Uric acid >6.5 mg/dL                           | n=71 (52.6%)           |
| Potassium (mEq/L)                              | 5.01 ± 1.00            |
| Potassium >5.1 mEq/L                           | n=55 (40.7%)           |
| Urea (mg/dL)                                   | 106.74 ± 39.40         |
| Urea >100 mg/dL                                | n=84 (62.2%)           |
| Creatinine (mg/dL)                             | 7.89 ± 2.32            |
| Creatinine >6.0 mg/dL                          | n=109 (80.7%)          |
| History of skin allergy                        | n=41 (30.4%)           |
| Use of calamine lotion                         | n=51 (37.7%)           |
| Use of erythropoietin                          | n=81 (60.0%)           |
| Use of topical steroids                        | n=14 (10.4%)           |
| Use of calamine lotion                         | n=36 (26.6%)           |
| Connective tissue disorder                     | n=5 (3.7%)             |
| Twice weekly hemodialysis                      | n=65 (48.1%)           |
| Thrice weekly hemodialysis                     | n=70 (51.9%)           |
| Pruritus absent                                 | n=85 (63.0%)           |
| Pruritus present                               | n=50 (37.0%)           |
| Frequency of pruritus: monthly                 | n=6 (4.4%)             |
| Frequency of pruritus: weekly                  | n=10 (7.4%)            |
On univariate regression model, factors found associated with pruritus were age >50 years (OR: 2.800 [1.237-6.336], p=0.013), female gender (OR: 2.532 [1.237-5.183], p=0.011), phosphate >4.5 mg/dL (OR: 3.556 [1.576-8.020], p=0.002), albumin <3.5 g/dL (OR: 4.278 [2.019-9.064], p<0.001), potassium >5.1 mEq/L (OR: 4.875 [2.89-10.381], p<0.001), presence of skin allergy (OR: 8.401 [3.665-19.257], p<0.001), and twice weekly dialysis (OR: 2.143 [1.052-4.367], p=0.036). On multivariate logistic regression, female gender (aOR: 3.592 [1.337-9.655], p=0.011), phosphate >4.5 mg/dL (aOR: 3.889 [1.118-13.532], p=0.033), albumin <3.5 g/dL (aOR: 2.987 [1.156-7.716], p=0.024), potassium >5.1 mEq/L (aOR: 2.934 [1.030-8.355], p=0.044), and presence of skin allergy (aOR: 8.100 [2.926-22.420], p<0.001) were independent factors associated with pruritus in hemodialysis patients as shown in Table 2.

### Table 1: Baseline data of the study population (n=135).

| Variables          | Odds ratio | 95% confidence interval | p-value | Adjusted odds ratio | 95% confidence interval | p-value |
|--------------------|------------|--------------------------|---------|---------------------|--------------------------|---------|
|                    | lower      | upper                    |         | lower               | upper                    |         |
| Age <50 years      | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Age >50 years      | 2.800      | 1.237                    | 6.336   | 0.013*              | 1.571                    | 4.716   | 0.421  |
| Gender (Male)      | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Gender (Female)    | 2.532      | 1.237                    | 5.183   | 0.011*              | 3.592                    | 9.655   | 0.011* |
| Diabetes (Absent) | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Diabetes (Present) | 1.688      | 0.831                    | 3.426   | 0.148               | -                        | -       |
| Hypertension (Absent) | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Hypertension (Present) | 1.039   | 0.460                    | 2.347   | 0.927               | -                        | -       |
| BMI <26 kg/m²      | 1.00       | -                        | -       | 1.00                | -                        | -       |
| BMI >26 kg/m²      | 1.333      | 0.657                    | 2.707   | 0.426               | -                        | -       |
| Phosphate <4.5 mg/dL | 1.00   | -                        | -       | 1.00                | -                        | -       |
| Phosphate >4.5 mg/dL | 3.556 | 1.576                    | 8.020   | 0.002*              | 3.889                    | 13.532  | 0.033* |
| PTH <300 pg/mL     | 1.00       | -                        | -       | 1.00                | -                        | -       |
| PTH >300 pg/mL     | 0.857      | 0.352                    | 2.086   | 0.734               | -                        | -       |
| Albumin >3.5 g/L   | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Albumin <3.5 g/L   | 4.278      | 2.019                    | 9.064   | <0.001†             | 2.987                    | 7.716   | 0.024* |
| Calcium >8.5 mg/dL | 1.00       | -                        | -       | 1.00                | -                        | -       |
| Calcium <8.5 mg/dL | 1.667      | 0.723                    | 3.843   | 0.231               | -                        | -       |
| Uric acid >6.5 mg/dL | 1.00   | -                        | -       | 1.00                | -                        | -       |
| Uric acid <6.5 mg/dL | 0.848 | 0.421                    | 1.706   | 0.644               | -                        | -       |
| Potassium <5.1 mEq/L | 1.00 | -                        | -       | 1.00                | -                        | -       |
| Potassium >5.1 mEq/L | 4.875 | 2.289                    | 10.381  | <0.001†             | 2.934                    | 8.355   | 0.044* |
| Urea <100 mg/dL    | 1.00       | -                        | -       | 1.00                | -                        | -       |

CKD: chronic kidney disease; BMI: body mass index; n: number of subjects; GFR: glomerular filtration rate.

**Table 2**
### TABLE 2: Univariate and Multivariate logistic regression model of study variables for pruritus.

* signifies p-value less than 0.05, ** signifies p-value less than 0.01, † signifies p-value less than 0.001.

EPO: erythropoietin; BMI: body mass index; PTH: parathyroid hormone.

ROC analysis showed serum potassium at a cut-off value 4.85 mEq/L with area under the curve (AUC) of 0.747, 80.0% sensitivity and 83.3% PPV is predictive of pruritus (p<0.001). Serum calcium at a cut-off value 7.65 mg/dL (AUC: 0.376) with sensitivity of 70.0% and NPV of 50.0% (p=0.017), serum albumin at a cut-off value 3.05 g/dL (AUC: 0.250) with sensitivity of 70.0% and PPV of 40.0% (p<0.001), serum phosphate at a cut-off value 4.45 mg/dL (AUC: 0.724) with sensitivity of 90.0% and PPV of 88.9% (p<0.001), and serum urea at a cut-off value 135.88 mg/dL (AUC: 0.665) with specificity of 94.1% and PPV of 72.7% (p<0.001) are predictive of pruritus presence in hemodialysis patients as shown in Table 3 and Figure 2.
| Variable                        | AUC   | S.E  | 95% Confidence interval | SEN  | SPE  | NPV  | PPV  | Youden's index | p-value |
|--------------------------------|-------|------|--------------------------|------|------|------|------|----------------|---------|
|                                | lower | upper|                          |      |      |      |      |                |         |
| Age (cut-off: 54.0 years)      | 0.544 | 0.050| 0.446 0.642              | 80.0%| 47.1%| 47.1%| 80.0%| 0.271          | 0.393   |
| BMI (cut-off: 26.65 kg/m²)     | 0.476 | 0.051| 0.376 0.577              | 50.0%| 58.8%| 41.7%| 66.7%| 0.088          | 0.649   |
| Calcium (cut-off: 7.65 mg/dL)  | 0.376 | 0.052| 0.275 0.478              | 70.0%| 17.6%| 50.0%| 33.3%| 0.008          | 0.017*  |
| Albumin (cut-off: 3.05 g/dL)   | 0.250 | 0.044| 0.164 0.336              | 70.0%| 11.8%| 31.8%| 40.0%| 0.008          | <0.001* |
| Uric acid (cut-off: 7.10 mg/dL)| 0.514 | 0.054| 0.408 0.619              | 40.0%| 78.8%| 52.6%| 69.1%| 0.018          | 0.793   |
| Potassium (cut-off: 4.85 mEq/L)| 0.747 | 0.047| 0.654 0.840              | 80.0%| 58.8%| 53.3%| 83.3%| 0.388          | <0.001* |
| Phosphate (cut-off: 4.45 mg/dL)| 0.724 | 0.045| 0.635 0.812              | 90.0%| 47.1%| 50.0%| 88.9%| 0.371          | <0.001* |
| PTH (cut-off: 134.50 pg/mL)    | 0.406 | 0.053| 0.303 0.509              | 90.0%| 17.6%| 39.1%| 75.0%| 0.076          | 0.068   |
| Urea (cut-off: 135.88 mg/dL)   | 0.665 | 0.051| 0.564 0.765              | 40.0%| 94.1%| 80.0%| 72.7%| 0.341          | 0.001*  |
| Creatinine (cut-off: 6.80 mg/dL)| 0.447 | 0.050| 0.349 0.545              | 80.0%| 41.2%| 44.4%| 77.8%| 0.212          | 0.305   |

**TABLE 3:** ROC analysis of descriptive variables for pruritus.

* indicates a significant p-value of less than 0.05.

ROC: receiver operating characteristics; AUC: area under the curve; S.E: standard error; SEN: sensitivity; SPE: specificity; PPV: positive predictive value; NPV: negative predictive value; PTH: parathyroid hormone; BMI: body mass index.
**FIGURE 2:** Showing ROC curves for each individual study variable for predicting pruritus.

ROC: receiver operating characteristic; PTH: parathyroid hormone; BMI: body mass index.

Figure 3 shows combined ROC curves for all study variables.
**FIGURE 3: Combined ROC curves of all study variables.**

ROC: receiver operating characteristic; PTH: parathyroid hormone; BMI: body mass index.

**Discussion**

Cutaneous manifestation frequently associated with end-stage renal disease is pruritus, and this symptom results in significant changes in the quality of life of the sufferer, sleep disturbances, and depression potentiating the risk of morbidity [3]. The majority of patients belonged to an age range of 50-61 years [2,3,5,10,11]. No gender discrimination was observed in the development of pruritus among patients of CKD in multiple studies [3,5,11,12], while a few studies reported increased prevalence in the male gender [2,10]. Studies usually categorized the patients of end-stage renal disease in the presence and absence of pruritus [3,5,12], while a couple of studies categorized patients according to the severity of pruritus i.e., mild, moderate, and severe [2,10]. Abundant studies reported no statistically prominent difference in terms of age, sex, duration of dialysis, etiology of uremia, levels of PTH, calcium, phosphorus, and creatinine in association with pruritus among patients of end-stage renal disease [2,5,10]. Another study conducted by Massry et al. reported significantly raised levels of phosphorus manifesting pruritus [11]. A study of the same accord regulated in the Portuguese population reported prominent changes in pre-dialysis urea levels, calcium, and creatinine in a majority of patients while a change in phosphorus level was not found as significant [3]. A study conducted within the population of Saudi Arabia reported a decline in levels of calcium in patients with CKD leading to pruritus, while higher concentrations of PTH were observed prominently in the age group of 15-35 years [12]. Calcium-phosphorus product (Ca-P product) was found to increase in a study regulated by Massry et al. [11], while no prominent association of Ca-P product was detected with pruritus in the other study [12]. Serum alkaline phosphatase (ALP) levels were found to be elevated in pruritus suffering from CKD patients in various studies [5,11]. Frequent comorbidity encountered among patients was diabetes mellitus [2,5]. Massry et al. reported an increased prevalence of bone disease and enlarged parathyroid along with hyperparathyroidism in patients with pruritus [11], while another study reported symptoms of neuropathy prominent in patients of chronic kidney disease with pruritus [5]. Akhyani and colleagues reported around 70% of their patients with generalized pruritus prominent at trunk and limbs with 31.4% of them developing it during or after dialysis [3].

Conventionally, pruritus is known to occur more with peritoneal dialysis [13]; however, no significant difference was reported in another study [14]. Multiple factors were reported to be associated with uremic pruritus, like inadequate dialysis, hyperparathyroidism, elevated Ca-P product, xerosis, raised serum magnesium, and aluminum concentrations [15]. Other less significant associations are anemia, vitamin-A, beta-2 microglobulin levels [16], human leukocyte antigen (HLA) B35, congestive cardiac failure, neurological disorder, and ascites. In our study, we demonstrated a significant association with hyperkalemia, hyperphosphatemia, hypoalbuminemia, female gender, and previous history of skin allergy. No significant associations were found with hypocalcemia, hyperparathyroidism, serum urea or creatinine, body mass index, diabetes, hypertension, connective tissue disorder, and frequency of dialysis. Our study findings of hyperphosphatemia were supported by Narita et al. [2], with an OR of 1.7 at a cut-off value of 6.6 mg/dL, however, our cut-off was 4.5 mg/dL with OR of 3.8 and an AUC of 0.724, sensitivity of 90% and PPV of 88.8%. The other findings of their study were contradicting with our results such as blood urea nitrogen.
The management of pruritus in CKD includes optimum dialysis frequency, optimum treatment of hyperparathyroidism [11], hyperphosphatemia [18], and hypermagnesemia [15], regular use of emollients (like calamine lotion was reported in our study with a non-significant association), improving dialysis efficacy, topical analogics (open-label use of the glycerol and paraffin containing emulsion caused substantial improvement of pruritus and quality of life of the hemodialysis patients in one study) [19], oral antihistamines [20], montelukast [21], gabapentin/pregabalin [22], and antidepressants [23]. In our study, we tried to address two of the most followed therapies prevalent in our population i.e., topical steroids and topical calamine lotion although both were found insignificantly associated with pruritus, however, known skin allergy was another common phenomenon present in our study in 3.04% individuals (with or without pruritus) and was found single most important and independent factor for pruritus followed by laboratory parameters. Therefore, pruritus is reported to be caused by multiple factors hence affects the quality of life, and is also associated with poor outcomes in chronic hemodialysis patients [2,4,15,24].

There were a few limitations of our study, as it was a single dialysis center assessment, the sample size was limited due to participants with multiple exclusion criteria like chronic liver disease (CLD), inadequate/non-compliance to the frequency of dialysis, and known use of therapies other than calamine/topical steroids. However, multiple factors were missing from analysis like anemia status, liver function enzymes especially alkaline phosphatase, and serum magnesium among others. Still, the study significantly correlated many factors with the occurrence of pruritus in hemodialysis patients, most likely were history of skin allergy and serum phosphate levels followed by others.

Conclusions

There is limited data suggestive of treating hyperparathyroidism, hyperphosphatemia, and elevated Ca-P product actually reduces uremic pruritus. However, many observational studies have been linking these factors independently to pruritus in hemodialysis patients. Apart from topical treatments, controlled studies product actually reduces uremic pruritus. However, many observational studies have been linking these factors independently to pruritus in hemodialysis patients. Apart from topical treatments, controlled studies must be conducted on the efficacy of different therapeutic regimens for the control of pruritus in CKD patients as it is associated with poor quality of life and mortality.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Dow University Hospital issued approval IRB/DUH/2021/742/021. Ethical approval was obtained from the institutional review board, and consent to participate was taken from all the study participants in an informed written manner. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Mettang T: Pruritus in renal disease . Itch: Mechanisms and Treatment. Carstens E, Akiyama T (ed): CRC Press/Taylor & Francis, London; 2014. 5:1-19.
2. Narita I, Alchi B, Omori K, et al.: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006, 69:1626-32. 10.1038/sj.ki.5000251
3. Tinóco JD, Paiva MD, Macedo BM, Cossi MS, Delgado MF, Lira AL: Pruritus in hemodialysis patients: association with phosphorus intake and serum calcium level. Rev Gauca Enferm. 2018, 59:e20170081. 10.1590/1985-1447.2018.2017-0081
4. Cheng TY, Tarng DC, Liao YM, Lin PC: Effects of systematic nursing instruction on a low-phosphorus diet, serum phosphorus level and pruritus of patients on haemodialysis. J Clin Nurs. 2015, 26:485-94. 10.1111/jocn.13471
5. Akhyani M, Ganji MR, Samadi N, Khamesan B, Daneshpazhooh M: Pruritus in hemodialysis patients . BMC Dermatol. 2005, 5:7. 10.1186/1471-5945-5-7
6. Waheed AA, Pedraza F, Lenz O, Isakova T: Phosphate control in end-stage renal disease: barriers and
opportunities. Nephrol Dial Transplant. 2013, 28:2961-8. 10.1093/ndt/gft244
7. Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011, 6:915-21. 10.2215/CJN.06040710
8. Rodriguez M, Lorenzo V: Parathyroid hormone, a uremic toxin. Semin Dial. 2009, 22:565-8. 10.1111/j.1525-139X.2009.00581.x
9. Rehman U, Khan TM: Validity and reliability of the Urdu version of the 5D itching scale to assess pruritus among patients with chronic kidney disease in Pakistan. BMC Nephrol. 2017, 18:502. 10.1186/s12882-017-0717-0
10. Cho YL, Liu HN, Huang TP, Tarrng DC: Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol. 1997, 36:553-43. 10.1016/s0190-9622(97)70240-8
11. Massry SG, Popovtzer MM, Coburn JW, Makoff DL, Maxwell MH, Kleeman CR: Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med. 1968, 279:97-700. 10.1056/NEJM196809262791308
12. Tajbakhsh R, Joshaghani HR, Bayzayi F, Haddad M, Qorbani M: Association between pruritus and serum concentrations of parathormone, calcium and phosphorus in hemodialysis patients. Saudi J Kidney Dis Transpl. 2013, 24:702-6. 10.4103/1319-2442.113858
13. Min JW, Kim SH, Kim YO, et al.: Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis. Kidney Res Clin Pract. 2016, 35:107-15. 10.1016/j.krcp.2016.02.002
14. Wu HY, Peng YS, Chen HY, et al.: A comparison of uremic pruritus in patients receiving peritoneal dialysis and hemodialysis. Medicine (Baltimore). 2016, 95:e2935. 10.1097/MD.0000000000002935
15. Graf H, Kovarik J, Stummvoll HK, Wolf A: Disappearance of uraemic pruritus after lowering dialysate magnesium concentration. Br Med J. 1979, 2:1478-9. 10.1136/bmj.2.605.1478-a
16. Gejyo F, Homma N, Suzuki Y, Arakawa M: Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med. 1986, 314:585-6. 10.1056/NEJM198602273140920
17. Zucker I, Yosipovitch G, David M, Gafter U, Boner G: Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol. 2005, 49:842-6. 10.1016/s0190-9622(05)00212-4
18. Chou FF, Ho JC, Huang SC, Sheen-Chen SM: A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg. 2000, 190:65-70. 10.1016/s1072-7515(99)00212-4
19. Balaskas E, Szeptetovski JC, Bessis D, et al.: Randomized, double-blind study with glycerol and paraffin in uremic xerosis. Clin J Am Soc Nephrol. 2011, 6:748-52. 10.2215/CJN.05400610
20. Swarna SS, Aziz R, Zubair T, Qadir N, Khan M: Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus. 2019, 11:e5256. 10.7759/cureus.5256
21. Mahmudpouar M, Roozbeh J, Raiss Jali GA, Pakettra M, Erzat Zadegan S, Saghbe MM: Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iran J Kidney Dis. 2017, 11:50-5.
22. Solak Y, Biyik Z, Atalay H, et al.: Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrolology (Carlton). 2012, 17:710-7. 10.1111/j.1440-1779.2012.01655.x
23. Chan KY, Li CW, Wong H, Yip T, Chan ML, Cheng HW, Sham MK: Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. J Palliat Med. 2015, 18:966-70. 10.1097/jpmt.2012.0504
24. Carmichael AJ, McHugh MJ, Martin AM: Renal itch as an indicator of poor outcome. Lancet. 1991, 337:1225-6. 10.1016/0140-6736(91)92898-c